Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI) and Novelion Therapeutics Inc. (NASDAQ:NVLN), are influenced by compare since they are both players in the Biotechnology. These factors are particularly influence the profitability, institutional ownership, analyst recommendations, risk, dividends, earnings and valuation of the two firms.

Earnings and Valuation

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Brainstorm Cell Therapeutics Inc.	N/A	0.00	8.29M	-0.42	0.00
Novelion Therapeutics Inc.	128.63M	0.17	113.47M	-6.05	0.00

Table 1 demonstrates Brainstorm Cell Therapeutics Inc. and Novelion Therapeutics Inc.’s gross revenue, earnings per share (EPS) and valuation.

Profitability

Table 2 has Brainstorm Cell Therapeutics Inc. and Novelion Therapeutics Inc.’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Brainstorm Cell Therapeutics Inc.	0.00%	-101.8%	-59.6%
Novelion Therapeutics Inc.	-88.21%	404.3%	-32.6%

Volatility & Risk

Brainstorm Cell Therapeutics Inc. has a 1.56 beta, while its volatility is 56.00% which is more volatile than Standard & Poor’s 500. Novelion Therapeutics Inc.’s 64.00% more volatile than Standard & Poor’s 500 which is a result of the 1.64 beta.

Liquidity

The Current Ratio of Brainstorm Cell Therapeutics Inc. is 3.3 while its Quick Ratio stands at 3.3. The Current Ratio of rival Novelion Therapeutics Inc. is 0.2 and its Quick Ratio is has 0.2. Brainstorm Cell Therapeutics Inc. is better equipped to clear short and long-term obligations than Novelion Therapeutics Inc.

Insider and Institutional Ownership

Institutional investors owned 11.8% of Brainstorm Cell Therapeutics Inc. shares and 76.5% of Novelion Therapeutics Inc. shares. About 11.2% of Brainstorm Cell Therapeutics Inc.’s share are owned by insiders. Comparatively, 0.7% are Novelion Therapeutics Inc.’s share owned by insiders.

Performance

Here are the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

	Performance (W)	Performance (M)	Performance (Q)	Performance (HY)	Performance (Y)	Performance (YTD)
Brainstorm Cell Therapeutics Inc.	-3.54%	-5.49%	-27.36%	-34.78%	-25.37%	-23.47%
Novelion Therapeutics Inc.	18.8%	63.05%	-71.25%	-71.39%	-67.14%	-63.14%

For the past year Brainstorm Cell Therapeutics Inc. was less bearish than Novelion Therapeutics Inc.

Summary

Brainstorm Cell Therapeutics Inc. beats Novelion Therapeutics Inc. on 5 of the 9 factors.

Brainstorm Cell Therapeutics Inc., a biotechnology company, develops adult stem cell therapies for neurodegenerative disorders that include amyotrophic lateral sclerosis, multiple sclerosis, ParkinsonÂ’s disease, and others. The company holds rights to develop and commercialize its NurOwn technology through a licensing agreement with Ramot of Tel Aviv University Ltd. Its NurOwn technology is based on a novel differentiation protocol, which induces differentiation of the bone marrow-derived mesenchymal stem cells into neuron-supporting cells and secreting cells that release various neurotrophic factors, including glial-derived neurotrophic factor, brain-derived neurotrophic factor, vascular endothelial growth factor, and hepatocyte growth factor for the growth, survival, and differentiation of developing neurons. The company was formerly known as Golden Hand Resources Inc. and changed its name to Brainstorm Cell Therapeutics Inc. in November 2004 to reflect its new line of business in the development of novel cell therapies for neurodegenerative diseases. Brainstorm Cell Therapeutics Inc. was founded in 2000 and is headquartered in Hackensack, New Jersey.

Novelion Therapeutics Inc., a biopharmaceutical company, develops a portfolio of therapies for individuals living with rare diseases. Its product portfolio includes MYALEPT (metreleptin), a recombinant analogue of human leptin, indicated as an adjunct to diet as replacement therapy to treat the complications of leptin deficiency in patients with congenital or acquired generalized lipodystrophy; and lomitapide hard capsule for the treatment of homozygous familial hypercholesterolemia in adults under the brand names of JUXTAPID and LOJUXTA. The companyÂ’s orphan drug-designated product candidate is zuretinol acetate, an oral synthetic retinoid, in late stage development for the treatment of inherited retinal disease caused by underlying mutations in retinal pigment epithelium protein 65 and lecithin: retinol acyltransferase genes. The company was formerly known as QLT Inc. and changed its name to Novelion Therapeutics Inc. in November 2016. Novelion Therapeutics Inc. was founded in 1981 and is headquartered in Vancouver, Canada.